Xiu-Min Lu

Xiu-Min Lu

Auto-generated profile, based on publicly available information

Xiu-Min Lu

College of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, 400054, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2013 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
YLYa-Jing Liu
Ya-Jing Liu
CZChang-Yang Zhou
Chang-Yang Zhou
CQChun-Hong Qiu
Chun-Hong Qiu
XLXiu-Min Lu
Xiu-Min Lu
YWYong-Tang Wang
Yong-Tang Wang
Chlorogenic acid (CA), is found in high abundance in the leaves of a number of plants and has antibacterial, antiphlogistic, antimutagenic, antioxidant and other biological activities. It reportedly possesses antitumor activity via the induction of apoptosis in chronic myelogenous leukemia (CML) cell lines, including U937 and K562 cells. However, the effects of CA on human acute promyelocytic leukemia (APL) HL‑60 cells remains unknown. In the current study, the ability of CA to cause G0/G1 cycle arrest and induce apoptosis in the treatment of human APL HL‑60 cells was investigated. Following 5 days treatment with 1, 5 and 10 µM CA, cell viability and the effects of CA on the growth of HL‑60 cells were investigated using a growth curve constructed using trypan blue staining. Induction of apoptosis and inhibition of cell proliferation were estimated using Wright's‑Giemsa staining, Hoechst 33342 and propidium iodide (PI) staining, DNA ladder analysis and flow cytometry, following 48 h cell treatment with various doses of CA. The results indicated that the growth of HL‑60 cells reached a plateau phase at 72 h and the proliferation inhibition rate of HL‑60 cells in CA‑treated groups was significantly higher compared with the control, in a time‑ and dose‑dependent manner. However, the level of apoptosis of HL‑60 cells treated with CA markedly increased and formed more apoptotic bodies compared with the cells with no drug treatment, according to the Wright's‑Giemsa staining, Hoechst 33342 and PI staining, respectively. Using DNA ladder analysis and flow cytometry it was shown that a significant characteristic DNA ladder was observed when treated with CA. CA was capable of arresting cell cycle at G0/G1 phase. Apoptosis of HL‑60 cells treated with CA for 48 h was promoted significantly in a dose‑dependent manner, as well as the inhibition of proliferation. The observations revealed that CA inhibits proliferation and induces preprophase apoptosis of HL‑60 cells. Thus, the concentration of 10 µM may be the optimal dose for treatment human acute promyelocytic leukemia.

1 December 2021 in Current Neuropharmacology
Verified
Journal Article
Open access
PDF file
XCXing-Dong Chen
Xing-Dong Chen
JTJun-Jie Tang
Jun-Jie Tang
SFShuang Feng
Shuang Feng
HHHua Huang
Hua Huang
FLFeng-Nian Lu
Feng-Nian Lu
YWYong-Tang Wang
Yong-Tang Wang
Chlorogenic acid (CGA) is a kind of traditional Chinese medicine, abundant in honeysuckle and eucommia, and has a wide range of biological activities, and pharmacological effects. Previous studies have shown that CGA can regulate learning, memory, cognitive ability, coupled with improvement to anxiety, depression, and other post-traumatic stress disorder (PTSD)-like symptoms. This article explores the protective effects of CGA on neurons through its anti-apoptotic effect, inhibition of neuroinflammation and oxidative stress, which may be the mechanisms of its improvement of PTSD-like symptoms. It may provide a new therapeutic strategy for the treatment of PTSD and its comorbidities.

1 April 2016 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
SFShi-Qi Fang
Shi-Qi Fang
YWYong-Tang Wang
Yong-Tang Wang
JWJing-Xiang Wei
Jing-Xiang Wei
YSYa-Hai Shu
Ya-Hai Shu
LXLan Xiao
Lan Xiao
XLXiu-Min Lu
Xiu-Min Lu

7 April 2015 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
YWYong-Tang Wang
Yong-Tang Wang
XLXiu-Min Lu
Xiu-Min Lu
KCKai-Ting Chen
Kai-Ting Chen
YSYa-Hai Shu
Ya-Hai Shu
CQChun-Hong Qiu
Chun-Hong Qiu
Regeneration in the central nervous system (CNS) of adult mammalian after traumatic injury is limited, which often causes permanent functional motor and sensory loss. After spinal cord injury (SCI), the lack of regeneration is mainly attributed to the presence of a hostile microenvironment, glial scarring, and cavitation. Besides, inflammation has also been proved to play a crucial role in secondary degeneration following SCI. The more prominent treatment strategies in experimental models focus mainly on drugs and cell therapies, however, only a few strategies applied in clinical studies and therapies still have only limited effects on the repair of SCI. Recently, the interests in immunotherapy strategies for CNS are increasing in number and breadth. Immunotherapy strategies have made good progresses in treating many CNS degenerative disorders, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), stroke, and multiple sclerosis (MS). However, the strategies begin to be considered to the treatment of SCI and other neurological disorders in recent years. Besides anti-inflamatory therapy, immunization with protein vaccines and DNA vaccines has emerged as a novel therapy strategy because of the simplicity of preparation and application. An inflammatory response followed by spinal cord injury, and is controled by specific signaling molecules, such as some cytokines playing a crucial role. As a result, appropriate immunoregulation, the expression of pro-inflammatory cytokines and anti-inflammatory cytokines may be an effective therapy strategy for earlier injury of spinal cord. In addition, myelinassociated inhibitors (MAIs) in the injured spinal cord, such as Nogo, myelin-associated glycoprotein (MAG) and oligodendrocyte- myelin glycoprotein (OMgp) are known to prevent axonal regeneration through their co-receptors, and to trigger demyelinating autoimmunity through T cell-mediated harmful autoimmune response. The antagonism of the MAIs through vaccinating with protein or DNA vaccines targeting Nogo, MAG, OMgp, and their co-receptors, may be an effective strategy for the treatment of SCI. However, immunotherapy such as anti-inflammtory therapy or vaccine targeting MAIs or their receptors, accompanied with the potential in risking autoimmune diseases. As a result, in order to optimize the anti-inflammtory therapy and design of protein or DNA vaccines for their use in the future clinical application, we need to further understand the possible mechanisms of neuroprotective immunity. This review presents recent advances in the development of immunotherapy strategies for the treatment of axonal degeneration and demyelination, and improvement of motor function after SCI.

22 September 2023 in Neuropharmacology
Verified
Journal Article
Closed access
XCXing-Dong Chen
Xing-Dong Chen
JWJing-Xiang Wei
Jing-Xiang Wei
HWHai-Yan Wang
Hai-Yan Wang
YPYu-Yuan Peng
Yu-Yuan Peng
CTCan Tang
Can Tang
YWYong-Tang Wang
Yong-Tang Wang

16 May 2022 in WIREs RNA
Verified
Journal Article
Closed access
XCXing‐Dong Chen
Xing‐Dong Chen
HLHui‐Lin Liu
Hui‐Lin Liu
SLSen Li
Sen Li
KHKai‐Bin Hu
Kai‐Bin Hu
QWQing‐Yun Wu
Qing‐Yun Wu
YWYong‐Tang Wang
Yong‐Tang Wang